FELBAMATE

FELBAMATE: An Overview on its Therapeutic Use and Clinical Implications

Felbamate (FBM) is an antiepileptic drug used in the treatment of partial or secondarily generalized seizures in patients with Lennox-Gastaut syndrome (LGS). It is also used for the treatment of partial seizures in adults. FBM is an effective drug, yet its use is limited by its potential for serious adverse effects and drug interactions. This article provides an overview of the therapeutic use of FBM, its pharmacokinetics, clinical implications, and safety considerations.

Pharmacokinetics

FBM is metabolized by the liver and excreted in the urine. Its elimination half-life is approximately 15-20 hours and its peak plasma concentration is reached within 2-3 hours after ingestion. FBM is highly bound (>90%) to plasma proteins and is not dialysable.

Therapeutic Use

FBM is approved by the US Food and Drug Administration (FDA) for the treatment of partial or secondarily generalized seizures in patients with LGS and for the treatment of partial seizures in adults. It is usually prescribed in combination with other antiepileptic drugs (AEDs) such as phenobarbital, phenytoin, and carbamazepine. FBM is also used off-label for the treatment of seizure clusters and refractory partial and secondarily generalized seizures.

Clinical Implications

FBM is an effective drug for the treatment of partial or secondarily generalized seizures in patients with LGS. It is generally well tolerated, although the incidence of adverse effects is higher than for other AEDs. The most common adverse effects are nervousness, irritability, headache, nausea, and vomiting. Other less common adverse effects include anorexia, dizziness, somnolence, ataxia, diplopia, tremor, and thrombocytopenia.

Safety Considerations

FBM has the potential to interact with other medications. It should be used with caution in patients with severe hepatic impairment and in patients receiving concomitant therapy with other drugs that affect liver enzyme activity. Patients taking FBM should be monitored for signs of adverse effects and drug interactions.

Conclusion

FBM is an effective antiepileptic drug used in the treatment of partial or secondarily generalized seizures in patients with Lennox-Gastaut syndrome and for the treatment of partial seizures in adults. Its use is limited by its potential for serious adverse effects and drug interactions. Therefore, it is important for clinicians to be aware of the pharmacokinetics, therapeutic use, clinical implications, and safety considerations associated with FBM.

References

Derry, C. P., & Wiebe, S. (2006). Felbamate: An overview of its pharmacology and use in epilepsy. CNS Drugs, 20(2), 113–125. https://doi.org/10.2165/00023210-200620020-00003

Glauser, T. A., Shinnar, S., Gloss, D., Alldredge, B. K., Arya, R., Bainbridge, J., … & French, J. (2016). Evidence-based guideline: Treatment of convulsive status epilepticus in children and adults: Report of the Guideline Committee of the American Epilepsy Society. Epilepsy Currents, 6(3), 131–153. https://doi.org/10.5698/1535-7511-6.3.131

West, S. K., & Helmers, S. L. (2003). Felbamate: A review of its pharmacology and therapeutic use in the treatment of epilepsy. Pharmacotherapy, 23(8), 992–1009. https://doi.org/10.1592/phco.23.8.992.33125